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ABSTRACT 
Alternative scaffolds are non-antibody proteins that can be engineered to bind new targets. They 
have found useful niches in the therapeutic space due to their smaller size and the ease with which 
they can be engineered to be bispecific. We sought a new scaffold that could be used for therapeutic 
ends and chose the C2 discoidin domain of factor VIII, which is well studied and of human origin. 
Using yeast surface display, we engineered the C2 domain to bind to αvβ3 integrin with a 16 nM 
affinity while retaining its thermal stability and monomeric nature. We obtained a crystal structure 
of the engineered domain at 2.1 Å resolution. We have christened this discoidin domain alternative 
scaffold the “discobody.” 
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C h a p t e r  1  
INTRODUCTION TO ALTERNATIVE SCAFFOLDS 
 
Monoclonal antibodies (mAbs) can be engineered to bind specific molecular targets with high 
affinity, and were heralded as being “magic bullets” to target cancer. Despite their increasing 
commercial success, mAbs have had limited therapeutic value for many diseases [1-4]. A richer 
understanding of how mAbs engage with and utilize the human immune system is beginning to 
change how mAbs are engineered [5]. Additionally, antibody engineering innovations [6] have lead 
to novel mAb formats, including bispecifics [7-9], small domains [10-12], and fusions to cytotoxic 
payloads [13] or nanoparticles [14]. Small domain alternative scaffolds such as fibronectin or 
DARPins are driving many of these later generation technologies [11,12,15]. While alternative 
scaffolds have demonstrated value in protein engineering and as reagents, their clinical utility is just 
beginning to be explored [10,16]. 
 
Antibodies 
The mAb immunoglobulin G (IgG) scaffold is a “Y” shaped 150 kDa glycoprotein made from a 
homodimer of heterodimers. Each homodimer half has a 50 kDa heavy chain (HC) made of four 
immunoglobulin domains, and a 25 kDa light chain (LC) made of two immunoglobulin domains. 
The HC and LC pair to form the fragment antigen-binding (Fab) region, which is involved in 
molecular recognition. There are two Fabs that make up the arms of the “Y” shape. The tail end of 
the mAb is the fragment crystallizable region (Fc), which mediates immune effector functions and 
the long serum half-life of mAbs (Fig. 1-1). 
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The Fab region of the mAb is evolved through a series of VDJ recombination gene rearrangements 
and somatic hypermutation evolution that introduces point mutations for greater stability of the 
mAb as well as affinity and specificity of antigen binding. Clones are filtered through a negative 
selection step that removes self-antigens during B-cell development in the immune system. 
Traditionally, an antigen of interest that has been tethered to or formulated with immune-
stimulating haptens is injected into a mouse. The murine immune system recognizes the antigen as 
foreign, and activates individual B-cell clones harboring a mAb sequence that recognize the foreign 
target. This clone is affinity matured and expanded, producing large amounts of antigen-specific 
antibodies. These B-cells can be isolated from the mouse spleen and fused with an immortalized 
myeloma cell line to produce hybridomas, which are then screened for the mAb of interest. These 
hybridomas can be multiplied and utilized to make clonal mAbs [17]. 
 
mAbs derived from non-human sources cannot effectively be used as human therapeutics due to 
their immunogenicity. Mouse mAbs form human anti-mouse antibodies (HAMA), which lead to 
neutralizing antibodies against the drug. Genetic engineering allowed for techniques to make mouse 
mAbs more “human” by replacing the majority of their sequence with the human homologue, 
which is less likely to produce a HAMA immune response. This was traditionally achieved through 
chimeric or humanized antibodies. Chimeric antibodies retain the mouse variable domain (Fv) 
grafted onto a human scaffold. The Fv region consists of the variable heavy (VH) and variable light 
(VL) domains. Examples of chimeric antibodies include cetuximab (Erbitux, Bristol-Myers Squibb, 
Eli Lilly and Company) and rituximab (Rituxan, Biogen Idec, Genentech/Roche). Humanized 
antibodies have an entirely human sequence except for the mouse antigen binding loops 
(complementarity determining regions, or CDRs). Trastuzumab (Herceptin, Genentech/Roche) is an 
example of a humanized mAb [17-19].   
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Fully human mAbs have been engineered using display technologies or genetically engineered 
mice with human antibody repertoires [20]. Phage display is the most prominent display method, 
and utilizes the M13 bacteriophage with antibody libraries fused to the viral p3 coat protein [21]. 
Yeast display is another useful technology that expresses antibody libraries on the yeast surface as 
Aga1p-Aga2p yeast mating protein fusions [22]. While larger libraries can be accessed using phage 
display (109-1011) than yeast display (107-109), the yeast eukaryotic protein processing system may 
allow for greater library expression [23]. Because display libraries are made from synthetic DNA, 
including cloned human B-cell sequence repertoires, it is possible to isolate fully human mAbs. 
Adalimumab (Humira, AbbVie) is an example of a fully human mAb from phage display. A 
number of genetically engineered mice with completely human B-cell repertoires have been 
created, including the XenoMouse, which lead to the discovery and commercialization of 
panitumumab (Vectibix, Amgen) [20,21].  
 
The Fc region of the mAb is critical for serum half-life and effector functions, such as antibody-
dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-
dependent cell phagocytosis (ADCP). mAbs usually have serum half-lives of two weeks, allowing 
for less frequent dosing of the drug. This is because the 150 kDa mAb size is larger than the 60 kDa 
glomerular filter cutoff which filters out smaller proteins, and the Fc region interaction with the 
neonatal receptor FcRn. FcRn is present on the surface of endothelial cells, which endocytose mAbs 
from the serum. Normally, endocytosed proteins are enclosed in vesicles with a pH of 6, and are 
targeted for lysosomal destruction. However, FcRn proteins in these vesicles bind mAbs via the Fc 
region at pH 6. FcRn complexed with the mAbs are returned to the surface of the cell and are 
exposed to serum, where the FcRn-Fc interaction dissociates at neutral pH 7.4. The Fc region also 
binds four different Fcγ receptors and the first component of complement for immune effector 
functions. FcγRI, FcγRIIa, and FcγRIIIa are activating receptors, while FcγRIIb is inhibitory. The 
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four isotyopes of human IgG bind each of these receptors with differing affinities, and therefore 
have varying effector functions. Fc regions can be engineered to modulate half-life and effector 
function [24-27]. 
 
Several early protein engineering advances demonstrated that the mAb IgG protein scaffold was not 
the only option for targeted protein therapy (Fig. 1-2). Etanercept (Enbrel, Amgen/Pfizer) is a 
chimeric tumor necrosis factor (TNF) inhibitor made by fusing the extracellular domain of TNF 
receptor 2 to an IgG1 Fc, essentially replacing the Fab portion of the mAb with a natural receptor 
(Fig. 1-2A) [28]. Domain antibodies (dAbs, GlaxoSmithKline) are VH domains engineered for 
binding and resistance to aggregation via phage display (Fig. 1-2B). It was hoped that dAbs would 
show better tissue and tumor penetration due to their small size, and that they could easily be 
tethered together to make bispecific molecules [29,30]. The 10th repeat of fibronectin III 
(fibronectin or Adnectin, Bristol-Myers Squibb) was the first alternative scaffold to be engineered. 
Fibronectin is a β-sandwich with three loops clustered on one end that resembles a dAb (Fig. 1-2C). 
Fibronectin exhibits thermal stability above 80°C and its binder derivatives have been extensively 
studied [31-38]. Etanercept, dAbs, and fibronectin have influenced subsequent mAb variants and 
alternative scaffolds for use as therapeutics.  
 
Despite the success of mAbs, they have inherent limitations that preclude certain applications. 
mAbs are large, multimeric, glycosylated, and bound by disulfides. This requires expression in 
expensive mammalian cell lines with slow turnaround times between batches, adding significantly 
to the time and cost of production for clinical trials. Additionally, they are moderately stable, and do 
not have long shelf lives compared to many smaller alternative scaffold domains [11,12,15,39]. 
Their homodimeric nature makes bispecific mAbs difficult to produce, and can require complex 
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engineering to ensure a heterodimeric mAb pair. Single-chain variable fragment (scFv) formats, 
which string together the VH and VL domains via a long glycine and serine rich (Gly-Ser) linker, are 
not stable [40]. Additionally, the use of Gly-Ser linkers can potentially be immunogenic [8]. While 
the 150 kDa size of mAbs is good for a long serum half-life, the large molecular weight can prevent 
deep tissue penetration and tumor uptake when compared with small domains [11,12,15,39]. 
Additionally, the complex patent situation around mAbs can make freedom to operate analyses 
difficult, since many alternative scaffolds have clear-cut intellectual property associated with them 
[41].   
 
Since Shohei Koide’s group demonstrated that fibronectin could be engineered to bind new targets 
[31], other non-antibody proteins have been explored as alternative scaffolds and have enjoyed 
varying degrees of success. Besides fibronectin, the most prominent examples include DARPins, 
Avimers, Anticalins, Affibodies, and peptide-based scaffolds [10,15,16]. Here we review the 
different scaffolds with a focus on protein engineering and clinical applications.  Structures of their 
respective folds are shown in Figure 3, with engineered regions highlighted in red [16,42-49]. 
 
Fibronectin 
The 10th repeat of the human fibronectin III domain is a 94 amino acid (10 kDa) β-sandwich with 
seven β-strands composing the core, and three loops clustered on one face that constitute the 
binding interface (Fig. 1-3A). These loops are the BC, DE, and FG loops, with FG being the largest. 
The total number of engineerable amino acids is 10 to 24 residues. Due to the high thermal stability 
of the parent scaffold, with a Tm above 80°C, sequence diversity, loop length variability, and 
mutations are well tolerated in engineered variants [10]. Fibronectin has been engineered using 
phage [31], yeast [36], and mRNA display [50]. mRNA display, and a related technique called 
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ribosome display, are in vitro technologies which are most useful for small domains and peptides 
[51].  
 
Using loop length variability and recursive mutagenesis in yeast display, Hackel et al. extended the 
affinity limit of the fibronectin scaffold to 1 picomolar against hen egg lysozyme [34]. This is the 
tightest known engineered protein-protein interaction, though some scFvs can bind hydrophobic 
molecules such as fluorescein with femtomolar affinities [52]. The bottom AB loop of fibronectin 
and the β-strands have also been engineered to bind targets, demonstrating the further utility of this 
scaffold [38,53].  
 
CT-322 (Angiocept, Bristol-Myers Squibb) is a polyethylene glycol (PEG)ylated fibronectin 
engineered against vascular endothelial growth factor receptor 2 (VEGFR-2). It binds both human 
and mouse receptors with high affinities, allowing for use of mouse xenograft models for preclinical 
testing. CT-322 blocks the interaction of VEGFR-2 with VEGF-A, VEGF-C, and VEGF-D. CT-
322 had a serum half-life of 100 hours, and in clinical trials demonstrated small decreases in tumor 
volume in 4/34 patients. 24 patients showed stable disease. Additionally, a PEGylated bispecific 
fibronectin against epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 
receptor (IGF1R) showed greater anti-proliferative effects against various human cancer cell lines 
than either single domain, demonstrating that the scaffold works in bispecific formats [16,54]. 
 
Fibronectin domains have been fused to mAbs to make multi-specific molecules. Two different 
fibronectins engineered to bind different epitopes of EGFR were coupled to an anti-EGFR mAb to 
form a triepitopic fusion protein, termed Ab-Fn3. Ab-Fn3 induced EGFR surface crosslinking and 
downregulation, even in cell lines resistant to anti-EGFR mAb monotherapy. EGFR is a target of 
interest in cancer, and can undergo downstream activating mutations that render the tumor resistant 
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to current mAb therapeutics [55]. Novel mAb formats such as Ab-Fn3 highlight the potential of 
therapies based on alternative scaffolds and mAbs. Folds similar to fibronectin have been 
engineered for use as therapeutics, including a domain from human tenascin C (Tn3, Medimmune) 
and a fibronectin consensus domain (Centyrin, Janssen Pharmaceuticals) [56,57]. 
 
DARPins 
DARPins, or designed ankyrin repeat proteins, are alternative scaffolds based on 33 amino acid 
repeating units. These repeats consist of a helix-turn-helix-β hairpin fold, and were engineered as 
consensus designs from human and non-human ankyrin repeat sequences. Jawless vertebrates use 
similar repeat proteins based on leucine-rich repeats for their immune system, demonstrating a 
natural precedent for using repeat-based non-antibody folds to provide protection against a broad 
array of foreign antigens. The average DARPin contains five internal repeats with an N- and C-
terminal cap to stabilize the protein, and are typically 130-200 amino acids long. DARPins are 
diversified along seven residues in the helices and some small loops of each subunit (Fig. 1-3B), 
and are not believed to change conformation when bound to antigen. With less entropy to lose upon 
binding, picomolar binders can be isolated from a single round of evolution. Additionally, they 
display extraordinary stability with a Tm of close to 100°C for four-repeat units, with stability 
generally increasing as more units are added [12,58,59]. DARPins have primarily been engineered 
via ribosome display [58], but phage display has also been used using the SRP signal sequence. 
Because of the fast folding rates of DARPins, traditional Sec-dependent phage display leads to 
cytoplasmic folding of DARPin libraries and precluded translocation to the periplasm, which is 
required for display [60,61]. 
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DARPins have been utilized in creative applications for therapeutics [16,58,59]. Of particular 
interest is viral retargeting to tumors for gene therapy. One study used a tetrameric DARPin 
expressed separately from the virus, with three of the DARPins binding an adenovirus surface 
protein. The remaining DARPin was used to target HER2 positive cells. Upon infection with the 
adenovirus-DARPin assembly, the cells showed a significant increase in luciferase transduction. 
Because the DARPin construct was expressed independently of the virus, complications associated 
with expressing virus fused to extraneous constructs were avoided [62]. DARPins have also been 
used to redirect adeno-associated viruses (AAVs) as direct coat-protein fusions [63].  
 
Because DARPins lack cysteines, they express well in bacterial hosts and can be site-specifically 
conjugated by the addition of individual cysteine residues, which are amenable to various 
bioconjugate chemistries. DARPins have been conjugated to protamine polymers complexed with 
small interfering RNAs (siRNAs), and demonstrated delivery of anti-bcl-2 siRNA to tumor cells via 
epithelial cell adhesion molecule (EpCAM) binding DARPins. EpCAM binding DARPins have 
also been attached to protein toxins such as Pseudomonas exotoxin A, and this fusion demonstrated 
potency against EpCAM-positive tumor cells. As with the Ab-Fn3 fibronectin example mentioned 
before, DARPins have been fused to form multiepitopic binders against EGFR. These molecules 
showed activity equivalent to, and in some cases better than, cetuximab, an EGFR targeting mAb. 
Anti-VEGF DARPins are undergoing phase II clinical trials for age-related macular degeneration 
(AGN 150998, Allergan) [16,58,59].  
 
Avimers 
Avimers, short for “avidity multimers,” are tandem 35 amino acid (4 kDa) alternative scaffolds 
based on the human A-domain. These A-domain derivates are strung together into a “pearls on a 
string” format. The A-domain contains three internal disulfide bonds and a stabilizing calcium ion 
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(Fig. 1-3C). Over 200 different A-domains are found in human proteins, including low-density 
lipoprotein receptors. 28 positions per subunit are used for diversity generation, similar to the 25-30 
residues involved in mAb binding. Avimer libraries were created using exon shuffling. Unlike other 
domains, where affinity maturation may be required, the first binding A-domain is subsequently 
tethered to a new library, where a second randomized A-domain separated by a five amino acid 
linker is generated. In this fashion, up to eight A-domains were engineered into a single Avimer. 
Avimers bind with subnanomolar affinities and can be expressed in high yields, even with eight 
domains linked together [41,64].  
 
Avimers have been tested clinically, and were found to have some advantages over their mAb 
counterparts. mAbs against c-met or CD28 cause adverse effects, possibly because each mAb has 
two Fab regions and can bind two antigens at once, leading to receptor clustering and activation. 
Avimers against these targets did not demonstrate negative effects because each Avimer only binds 
a single antigen, although on multiple epitopes. An anti-IL-6 triepitopic Avimer inhibited IL-6-
induced cell proliferation and showed activity in mice. Since Avimers are small proteins, they are 
rapidly cleared from the serum through the kidneys. This problem was solved by tethering an anti-
IgG domain as part of the Avimer to take advantage of the natural serum half-life extension of the 
IgG-FcRn interaction [16]. Amgen has since acquired Avimer technology for further development.  
 
Anticalins 
Anticalins are engineered from the human lipocalin family. Lipocalins are 170 amino acid (20 kDa) 
β-barrels with eight β-strands that support four binding loops (Fig. 1-3D). They are found in plasma, 
and secreted/tissue fluids. They do not contain disulfides, have Tms above 70°C, and can express 
well in bacterial hosts. They are unique in that they have a relatively large opening in the binding 
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interface that can accommodate small molecule binding in a cavity made by the binding loops 
and β-barrel structure. In nature, this cavity is used to bind small molecule vitamins and hormones 
for transport, storage, and sequestration. Anticalin libraries can be made with 16-24 random 
residues in the loops as well as select residues in the small molecule binding pocket, allowing for 
great diversity generation. Due to their unique structure, they can be engineered to bind proteins or 
small molecules [16,65,66].  
 
Anticalins have been conjugated to fluorescent molecules via site-specific cysteine insertions, or 
PEGylated for extended half-life. PEGylated Anticalins against VEGF showed anti-angiogenic and 
anti-tumor activity in mouse xenograft models. PRS-050, a site-specifically PEGylated Anticalin 
that binds to all splice forms of human VEGF-A as well as rodent orthologues, was tested in a phase 
I dose escalation study. PRS-050 showed no immunogenicity, with only a single patient (out of 26) 
showing ADAs after 17 doses. Half-life was approximately six days, and no free VEGF-A was 
detected after drug treatment, while PRS-050-VEGF-A complexes were detected up to three weeks 
after dosing [67]. Bispecific Anticalins, called duocalins, have been made to target two antigens at 
once [16]. A89Zn-labeled anti-MET Anticalin was used to visualize MET-positive tumor expression 
in mouse models via positron-emission tomography (PET) imaging. Tumor uptake was shown to be 
dose-dependent [68]. Pieris AG is the company developing Anticalins.  
 
Affibodies 
Affibodies are derived from protein A, a Staphylococcus aureus protein that is used widely in 
industry to purify mAbs based on protein A’s interaction with the Fc domain. Affibodies are 
engineered from the B-domain of protein A, and have been modified to remove their Fc binding 
while increasing stability. The structure consists of a 58 amino acid (6 kDa) three-helix bundle 
without any cysteines. The antigen-binding portion consists of randomized side chains on two of the 
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three α-helices (Fig. 1-3E). Anti-HER2 Affibodies have been generated with affinities down to 
22 picomolar [16,69].  
 
Radiolabelled variants were used to image HER2-positive xenograft tumors with high contrast in 
mouse models. Anti-HER2 Affibodies fused to albumin binding domains lead to molecules with 
increased serum half-life due to the long circulation times of albumin, and had a concomitant 
increase in tumor uptake. Anti-HER2 Affibodies were fused to Pseudomonas exotoxin A and killed 
BT-474 breast cancer cells in tumor xenograft models. EGFR binding Affibodies were also 
generated for radiolabelled imaging and showed accumulation in tumors. Anti-EGFR Affibodies 
were tethered via a Gly-Ser linker to anti-HER2 Affibodies to make bivalent molecules, since both 
HER2 and EGFR are co-expressed on some tumor types [10,16,69].  
 
Affibodies have also been developed as Fc fusions and in large complexes for drug delivery via 
viruses, nanoparticles, and liposomes. Affibodies are of particular interest in imaging due to their 
small size and rapid plasma clearance, which can increase contrast ratios. They have been 
conjugated to fluorescent proteins, dyes, and radiolabels for such applications [69]. Affibody AB is 
developing the Affibody technology. 
 
 
Peptides 
Small peptide-based binders have been engineered using a variety of scaffolds such as knottins, the 
Kunitz domains, and naturally occurring toxins. These domains are 30-60 amino acids (3-7 kDa), 
and contain several internal disulfide bonds. Due to their small size and rigid structures, most 
engineered peptide-based binders are based on loop grafts or have been evolved to enhance their 
natural binding activities. Some of these peptide scaffolds have been engineered for specific 
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selectivity profiles, since many of their parental molecules demonstrate promiscuity in binding 
partners [10,16,39]. The universal applicability of these small scaffolds to create de novo binders 
has yet to be demonstrated.  
 
Knottins are 30 amino acid (3 kDa) cystine knot proteins with three internal disulfide bonds that 
confer stability onto the protein, preventing denaturation even in extreme acid or base conditions. 
Several knottins, including the human Agouti-related protein (Fig. 1-3F) and the Ecballium 
elaterium trypsin inhibitor were engineered with RGD-based libraries to bind to integrin. Variants 
with different subtype selectivity profiles against αvβ3, αvβ5, and αvβ1 integrin were engineered 
with affinities down to 10 nanomolar. These peptides were selected for in yeast display, and binders 
were synthesized chemically for testing [70,71]. The molecules have been labeled for PET imaging 
in early cancer detection [72,73]. ω-conotoxins are another class of disulfide-rich peptides, in this 
case derived from the cone snail Conus magus [74]. SNX-111 (Ziconotide, Prialt) is a Food and 
Drug Administration (FDA) approved therapeutic for chronic pain that blocks N-type voltage-gated 
calcium channels [75].  
 
Kunitz domains are peptide-based protease inhibitors that are 60 amino acids (7 kDa) in size. They 
inhibit proteases, including serine proteases such as trypsin [16]. Kunitz domains are also disulfide 
rich, with three internal disulfides that hold together three loops involved in binding. The 
Alzheimer’s amyloid β-protein precursor Kunitz domain (Fig. 1-3G) was engineered with phage 
display to selectively inhibit human plasma kallikrein. Libraries with random residues near the 
binding loop were selected against immobilized kallikrein, and variants with inhibition constants 
(Ki) down to 75 picomolar were isolated [76-78]. Other Kunitz domain engineering work based on 
the human lipoprotein associated coagulation inhibitor lead to the identification of ecallantide 
(Kalbitor, Dyax), an FDA approved therapeutic for hereditary angioedema [79]. 
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Νext generation alternative scaffolds  
Alternative scaffolds have been engineered to bind a variety of targets, and have been linked 
together to make multi-specific molecules. Exciting next generation applications of alternative 
scaffolds are beginning to emerge, including mAb fusions targeting up to five ligands at once, small 
bicyclic peptides with chemically conjugated hydrophobic cores, and engineered super ligands that 
are tailor-made to modulate specific biological pathways.  
 
The aforementioned triepitopic Ab-Fn3 against EGFR demonstrated receptor clustering and 
efficacy against monotherapy resistant cell lines. This concept has also been demonstrated against 
five different antigens at once using mAbs fused to small alternative scaffolds. These molecules are 
known as zybodies (Zyngenia). By tethering Affibodies, knottins, or peptides (referred to as 
“modular recognition domains,” or “MRDs” in this study) with varying degrees of structure to the 
N- and C-termini of HER2 or EGFR targeting mAbs, zybodies showed better efficacy than 
trastuzumab (anti-HER2) in an angiogenesis-dependent xenograft tumor model [80].  
 
Small-molecule conjugated bicyclic peptides were engineered using a modified phage display to 
create rigid cyclic peptides with synthetic cores for added stability. Peptide libraries with diverse 
loops interspersed by three fixed cysteine residues were designed. These cysteine residues were 
conjugated to tris-(bromomethyl)benzene (TBMB), an aromatic ring with three thiol-reactive 
groups. To reduce background binding to the phage itself, a cysteine free D1-D2 domain of the p3 
fusion protein was utilized. Conjugated phage showed reduced infectivity, possibly due to 
background conjugation of the TBMB molecule to surface lysines. By randomizing two six-residue 
loops between the three cysteines, bicyclic peptides against kallikrein were engineered with Kis of 
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1.5 nanomolar. The bicyclic peptides can be synthesized chemically [81], and Bicycle 
Therapeutics is developing the technology for clinical use.  
 
Interleukins (IL) are immune signaling molecules that bind to receptor complexes consisting of 
different subunits. Affinity towards the receptor depends on which subunits interact with the bound 
IL. IL-2 is one such molecule that exerts immune stimulating effects. The IL-2 receptor consists of 
α, β, and γ subunits that all form interactions with the IL-2 ligand. IL-2 can bind to the αβγ complex 
with high affinity, or the βγ complex alone with a lower affinity. IL-2 variants were made to bind 
either the αβγ or βγ complexes with increased affinity, allowing selective IL-2 activation on 
different receptor assemblies. Certain cell types, such as leukocytes, that are targets of IL-2 
activation can be specifically modulated by the βγ binding IL-2 variant. Using this strategy, 
background cells which express the αβγ complexes, such as lung endothelial cells, can be avoided 
[82]. 
 
Factor VIII 
Factor VIII (fVIII) is a blood-clotting protein that is encoded by the F8 gene. Defects in the F8 gene 
cause hemophilia A, which is usually inherited as an X-linked recessive gene, but can also arise 
from spontaneous mutation. fVIII is a 2332 amino acid (330 kDa) protein that consists of six 
domains (A1-A2-B-A3-C1-C2) that are expressed as a single polypeptide from vascular and tubular 
endothelium, as well as sinusoidal cells of the liver. The six-domain fVIII protein is proteolytically 
cleaved and the B domain is removed, leaving a heterodimer of A1-A2 that is complexed with A3-
C1-C2. This heterodimer circulates in the serum with an additional protein called the von 
Willebrand factor (VWF). Upon injury, fVIII is further processed to fVIIIa, a heterotrimer of A1, 
A2, and A3-C1-C2, which is released from VWF and binds to platelet membranes. The C2 domain 
is responsible for binding to phosphatidylserine (PS) rich membranes on activated platelet cells. 
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fVIIIa binding to membranes catalyzes the interaction of factors IXa and X (fIXa, fX), which 
leads to further downstream processing that ultimately results in coagulation [49,83-88]. 
 
Patients with hemophilia A are missing or lack sufficient quantities of fVIII, and they require 
infusions of fVIII derived from natural or recombinant sources. fVIII can be isolated from donated 
blood (Hemofil M and Monarc-M, Baxter; Monoclate-P, ZLB Behring). Naturally derived fVIII 
requires extensive purification due to cases of contaminating HIV or hepatitis in the 1980s. 
Recombinant fVIII is also available (Advate and Recombinate, Baxter; Helixate FS and Kogenate 
FS, Bayer; ReFacto, Wyeth), and avoids the problems of serum virus contamination. Hemophiliac 
patients who lack natural fVIII and receive fVIII infusions sometimes form ADAs against the 
foreign protein. Additionally, fVIII has a short serum half-life at 8-12 hours, requiring many 
injections [89-91]. Newer fVIII technologies are being developed to overcome these shortcomings. 
mAbs have long serum half-lives due to their Fc regions, which interact with FcRn receptors. Fc 
fusion proteins have been made for a variety of proteins. fVIII was fused to an Fc to make rVIIIFc, 
which demonstrated a 1.54-1.7 fold longer t1/2 in human patients, potentially requiring less frequent 
dosing [92]. PEGylated fVIII variants demonstrated extended serum half-life and reduced ADA 
formation in mouse models [93]. Gene therapy can be used to introduce a gene encoding for 
functional fVIII, and has shown promise in a variety of animal models [94]. A particularly creative 
approach was to replace fVIII with a bispecific mAb that can bind both fIXa and fX, replacing 
fVIII’s natural function of clustering these two proteins. This approach successfully catalyzed the 
downstream coagulation processes necessary for blood clotting. Additionally, no ADAs against the 
mAb were formed, and the mAb demonstrated a serum half-life of two weeks [95]. This was tested 
in a nonhuman primate model, and may allow for innovative therapeutics for hemophiliacs.  
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The C2 domain of fVIII is of critical importance.  Hemophilia A can also be acquired through 
autoimmune antibodies against the C2 domain, and ADAs that form against the C2 domain of fVIII 
drugs can lead to decreased efficacy [89]. The HAMSTeRS database (Hemophilia A Mutation, 
Structure, Test, and Resource Site) is a compilation of fVIII genetic mutations [96]. The C2 domain 
has been co-crystallized with a variety of inhibitory mAbs. Additionally, alanine scanning 
mutagenesis, which tests the importance of certain residues for binding, has been performed on the 
C2 domain. These mutants were tested for binding to a panel of inhibitory mAbs, helping identify 
which residues can be engineered to avoid B-cell epitopes for future drug development [97].  
 
Discoidin Domain Family 
The C2 domain is part of the discoidin domain family, a 150 amino acid (18 kDa) domain that 
mediates many biological processes, including cellular adhesion, vasculogenesis, angiogenesis, 
migration, and development. DDR1 and DDR2 are receptor tyrosine kinases that contain the 
discoidin domain and are involved in extracellular matrix remodeling, cell adhesion, and 
proliferation. Neurexins and neuropilins also contain discoidin domains, and are important in 
nervous system development. Discoidin domains bind to a variety of cognate ligands such as 
galactose, collagen, growth factors, phospholipids, and other non-charged lipids. Discoidin domains 
are found as subunits of larger proteins, and can be arrayed in a repeated fashion or found as single 
units within the protein. The domain was first identified in the amoeba Dictyostelium discoideum, 
and was described as a lectin that bound galactose with high affinity (10-6 to 10-8 M Kd). Since then, 
genome sequencing has identified over 100 eukaryotic and 300 prokaryotic proteins that contain the 
discoidin domain [98-101].  
 
Over 20 X-ray and NMR structures of the discoidin domain, either alone or in its parental protein, 
have been solved to date. The structure consists of eight β-strands that form a distorted β-barrel. The 
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β-strands support three conformationally flexible spikes on one end that make up the binding 
interface (Fig. 1-3H). While the core β-barrel structure is fairly conserved within the discoidin 
domain family, the three binding spikes demonstrate diversity as result of the range of ligands that 
the family can bind to. However, each individual discoidin domain is only known to bind to a single 
cognate ligand [101].  The fVIII discoidin domain contains hydrophobic residues at the ends of 
spikes one and three. These intercalate into phospholipid membranes, and have positively charged 
residues at the base of the spikes that interact with the negatively charged phospholipid head groups 
[83,86]. In the case of the Dictyostelium discoideum discoidin domain, the spikes specifically 
coordinate binding to galactose residues to provide specific binding. The N- and C-termini of the 
discoidin domain are adjacent to one another, and bound by a disulfide in eukaryotic discoidin 
domains. The discoidin domain is believed to have originated from a single gene. Its modular 
architecture facilitates evolution into new proteins via domain shuffling [98-101].  
 
Discobody Alternative Scaffold 
The C2 domain exhibits several useful properties that make it attractive as an alternative scaffold. It 
is small, monomeric, and of human origin [87]. Additionally, the PS binding spikes have been 
mutated to no longer interact with the cognate PS membranes or VWF factor [83]. The large body 
of knowledge related to C2 mutations and fVIII engineering as a therapeutic are useful for protein 
engineers trying to manipulate C2 function for novel purposes [86,88,97]. Towards this end, we 
engineered the C2 domain of fVIII to bind to a new protein target - αvβ3 integrin. αvβ3 integrin is a 
cell surface protein involved in cell adhesion and migration during development, and is 
overexpressed in a number of tumors, where its dysregulation is associated with angiogenesis and 
metastasis [102,103].  
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Our work is the first demonstration that the discoidin domain scaffold can be engineered for non-
cognate binding purposes. We call engineered discoidin domains “discobodies.” Engineering the C2 
domain of fVIII may also illustrate ways to further engineer fVIII for next generation hemophilia A 
therapeutics.  
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Figures 
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Fig. 1-1. Domain schematic of a mAb. (A) Upper left: Fv in light blue, with VL and VH domains 
labeled. Fv is part of the Fab region shown in light blue and grey. There are two Fab fragments on 
the upper left and upper right, only the left one is annotated in this figure. Bottom: Fc region shown 
in purple and green. Upper right: HC and LC are shown in green and red, respectively. There are 
two HCs and LCs per mAb, only the right side is annotated in this figure. Regions of the mAb with 
overlapping nomenclature and are colored and labeled differently on each side. The axis of 
symmetry between each homodimer of heterodimers is shown as a dashed line bisecting the Fc 
region. (B) Legend summarizing the color schematics. 
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Fig. 1-2. Early mAb alternatives. (A) Etanercept, or Enbrel, a chimeric protein consisting of the 
extracellular domain of TNF receptor 2 in red fused to the Fc region of an IgG1 in grey. (B) 
Domain antibody, or dAb, shown in light blue. (C) Fibronectin domain shown in orange. (D) 
Legend summarizing colors and labels.   
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Fig. 1-3. Alternative scaffold structures in grey with engineerable binding interfaces highlighted 
in red. (A) Fibronectin, (B) DARPin, (C) Avimer subunit with stabilizing calcium ion shown in 
pink, (D) Anticalin, (E) Affibody, (F) knottin, (G) Kunitz domain, and (H) the discoidin domain 
(modified form PDB IDs 1FNA, 2V5Q, 1AJJ, 3BX7, 3MZW, 1HYK, 1KTH, and 2R7E, 
respectively). 
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C h a p t e r  2  
DISCOBODY ENGINEERING AND CHARACTERIZATION 
 
Monoclonal antibodies (mAbs) are an important part of the biotechnology industry and have 
demonstrated value as therapeutics, as research reagents, and in diagnostic assays [1-3]. mAbs 
can be engineered to bind specific molecular targets with high affinity.  However, this ability is 
not limited to mAbs, as in recent years alternative scaffolds based on fibronectin, protein A, 
ankyrin repeats, lipocalins, and other proteins have been engineered to bind various antigens. 
Alternative scaffolds can be engineered to have binding affinities and specificities characteristic 
of mAbs. Many of these scaffolds have also demonstrated superior biochemical and biophysical 
properties, such as high bacterial expression levels and thermal stability [15]. These attributes are 
important for reagents and diagnostic tools, where low material cost and high thermal stability (to 
facilitate storage and use in real-world conditions) are priorities [1,104,105].  
 
The therapeutic utility of alternative scaffolds is assessed with different criteria [11,106]. 
Immunogenicity is a critical issue for any protein therapeutic. Because immunogenicity remains 
difficult to predict a priori [106], it is important to mitigate this risk by starting with a human 
protein [11]. The first mAbs were of non-human origin and, despite successes in laboratory 
settings, were not suitable as human drugs. They were too immunogenic for repeated dosing and 
required humanization to make them useful as a therapeutic [107]. In contrast, scaffolds derived 
from human proteins, such as fibronectin [31], have elicited less immunogenic responses in 
patients. A Phase I trial of CT-322, a fibronectin engineered to bind VEGFR-2, only showed anti-
drug antibodies (ADAs) against the engineered binding loops and not the scaffold itself. 
Importantly, the ADAs did not affect plasma levels of CT-322 or a VEGF-A biomarker, and were 
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not associated with any adverse events [54]. It remains to be seen whether alternative scaffolds 
built from consensus designs [combinations of homologous sequences that were fully [57] or 
partially [108] derived from human proteins] will form ADAs upon repeated intravenous 
injections [106]. Other alternative scaffolds from non-human sources, such as camelid 
nanobodies, have been humanized prior to clinical use [109].  
 
Alternative scaffolds have been touted for their small size, which could lead to enhanced tumor 
penetration [11,15,105,110]. Additionally, monomeric scaffolds can be strung in tandem to form 
bispecifics that target two different antigens, or recognize two different sites on the same antigen 
and thus enhance binding. Bispecifics have been created using fibronectin [37], camelid 
nanobodies [111], DARPins [112,113], and more [15]. Another use of alternative scaffolds is to 
tether them to mAbs to form multi-specific molecules. Various proteins have been appended to 
mAbs including fibronectin [55], peptides, knottins, and affibodies [80]. The majority of these 
domains have N- and C-termini on opposing ends of the molecule (Fig. 2-1A, C, D, and F). This 
architecture requires a long and potentially immunogenic linker [8] when connecting tandem 
domains (Supplementary Fig. 2-S1A).  
 
Despite the promising results with existing scaffolds, new alternative scaffolds tailored for use as 
bispecific therapeutics are still needed. Here, we present an alternative scaffold based on the C2 
discoidin domain of human factor VIII (fVIII). We call this discoidin domain-based scaffold the 
“discobody,” or “Db.” Discobodies are of human origin and have favorable N- and C-termini 
geometries that may facilitate bispecific tethering. The N- and C-termini are adjacent to one 
another and are linked by a disulfide bond (Fig. 2-1B and E). Tandem domains facing opposite 
directions to maximize binding to two targets should not require a substantial linker, as is needed 
for other alternative scaffolds (Supplementary Fig. 2-S1B).  
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fVIII is a blood coagulation protein encoded by the F8 gene, which is involved in the formation 
of blood clots after injury. Mutation to the F8 gene results in the medical condition hemophilia A, 
requiring hemophiliacs to receive injections of functional fVIII to aid blood clotting [85,114]. 
The C2 domain of fVIII is an 18 kDa distorted β-barrel that contains three loops, or “spikes,” on 
its binding interface. Spikes 1 and 3 extend the farthest and contain hydrophobic residues at their 
ends. The native function of these spikes is to insert into phosphatidylserine (PS)-rich platelet 
membranes to initiate the coagulation cascade [83,87]. An important feature of our chosen 
scaffold is that it is based on the β-barrel topology. β-barrel folds are similar to the β-sandwich 
structures of the canonical mAb immunoglobulin and fibronectin scaffolds. Much like the mAb 
immunoglobulin and fibronectin folds, the discoidin β-barrel has loops clustered on one end [101] 
that may be engineered to bind specific antigens (Fig. 2-1).  
 
Due to its importance in fVIII function, the C2 domain has been extensively studied [84]. The 
domain can be expressed independently of fVIII, and positions on the spikes have been identified 
that abolish wild-type PS recognition, thereby providing a template for future engineering efforts 
[83,87]. The discoidin domain is a ~150 amino acid domain that is found in over 100 eukaryotic 
and 300 prokaryotic proteins and is often involved in cellular adhesion and development. The 
discoidin family demonstrates high sequence diversity in the spike regions, with different 
discoidins able to bind to a variety of different cognate lipids, carbohydrates, and proteins [101]. 
This inherent ability to encode natural diversity in one scaffold means the fold can tolerate 
different sequences and should therefore be amenable to the production of synthetic libraries. Its 
small size, monomeric nature, tolerance to mutation, and extensive biochemical characterization 
all make the C2 domain an attractive protein for alternative scaffold design [12].  
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We chose to validate the fVIII C2 scaffold by engineering a binder against αvβ3 integrin, a cell 
surface protein and a target of interest in oncology [102]. Additionally, αvβ3 is a well-studied 
protein and is known to interact with the linear Gly-Arg-Gly-Asp-Ser (GRGDS) peptide, 
exhibiting a 740 nM IC50 in extracellular matrix (ECM) competition assays [115]. The Arg-Gly-
Asp (RGD) motif is found in ECM proteins such as fibronectin and is used by αvβ3 integrin-
expressing cells as footholds to navigate the ECM for cellular motility [116]. αvβ3 integrin is 
overexpressed in a number of cancers [103], and the RGD-αvβ3 interaction contributes to tumor 
growth, angiogenesis, and metastasis. Blocking this interaction could provide therapeutic value 
[102]. We sought to build an RGD-based library of discobody variants and select for binders 
against αvβ3 integrin.  
Materials and Methods 
Reagents and strains 
αvβ3 integrin was purchased from R&D Systems. Yeast display Saccharomyces cerevisea strain 
EBY100, yeast display plasmid pPNL6, yeast secretion strain YVH10, and yeast secretion 
plasmid pPNL9 were obtained from Pacific Northwest National Laboratory. All yeast display 
protocols, buffers, and reagents were used as previously described [22,70]. Oligonucleotides were 
obtained from Integrated DNA Technologies, and PCR assembly primers were designed using 
DNAWorks from NIH’s Helix Systems [117]. KOD Hot Start Polymerase from Novagen was 
used to PCR assemble gene inserts. The inserts had flanking 20-40 bp overlaps with the desired 
cloning site in their respective, linearized plasmids. These were assembled into the appropriate 
plasmids using either yeast homologous recombination or Gibson cloning into TOP10 
Escherichia coli cells. Gibson cloning used reagents previously described [118], and constructs 
cloned into TOP10 competent cells were subsequently mini-prepped and transformed into yeast 
or BL21 (DE3) E. coli for protein expression. Bacterial expression used the pET11a vector with 
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Strep-Tag II cloned onto the C-terminus. Purification resins included HIS-select HF Nickel 
Affinity Gel from Sigma and StrepTactin Sepharose High Performance from GE Healthcare Life 
Sciences. Unless otherwise stated, all chemicals were from Sigma, and all E. coli strains from 
Life Technologies. Soluble protein expression was performed in 2.5 L Ultra Yield Flasks from 
Thomson.  Protein was concentrated in Amicon 10,000 Da MWCO centrifugal filters from EMD 
Millipore. DNA extraction was performed with kits from Qiagen. 
Loop grafts, library construction, flow cytometry, and sorting 
RGD-based integrin binding loops from six different engineered knottin peptides [70,71] and 
from wild-type fibronectin [43] were grafted into the spike 1 region of the discobody starting 
template (4-Ala C2 discoidin domain of fVIII). Yeast displayed protein was expressed at 20ºC 
and 250 RPM for 16 hours. Displayed protein was incubated with αvβ3. Flow cytometry was 
performed on a BD Biosciences FACSCalibur, and data was analyzed with FlowJo from Tree 
Star. 50,000 cell counts were collected for loop graft binding experiments. All yeast display 
experiments were performed in Integrin Binding Buffer (IBB) as previously described [70]. 
Libraries were constructed by high efficiency yeast electroporation [22]. FACS was performed on 
the MoFlo XDP instrument from Beckman Coulter using polypropylene BD Falcon FACS tubes. 
Sorted sequences were represented using WebLogo [119].  
Expression and characterization of soluble discobodies 
Discobodies were expressed both in YVH10 yeast secretion culture and BL21(DE3) E. coli. 
YVH10 transformed with a discobody construct in pPNL9 with a TEV-cleavable 6HIS tag were 
grown overnight in 4L of SDCAA–Ura. This was spun down and transferred to YPGR media (1% 
yeast extract, 2% bacto peptone, 2% galactose, 2% raffinose, 0.1% dextrose; denoted in w/v, 
yeast media components from BD Biosciences, sugars from Sigma) with penicillin-streptomycin 
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from Life Technologies. This culture was expressed at 20ºC, 200 RPM, for 48 hours. Pellets 
were spun down and discarded twice, and the supernatant was ammonium sulfate (VWR) 
precipitated at 80% salt. Precipitate was resuspended in YVH10 binding/wash buffer (300 mM 
NaCl, 20 mM sodium phosphate, pH 7.8, 0.05% tween 20, 2.5% glycerol, 10 mM imidazole) and 
loaded onto HIS-select resin. After washing with the same buffer, samples were eluted in YVH10 
elution buffer (300 mM NaCl, 20 mM sodium phosphate, pH 7.8, 0.05% tween 20, 2.5% 
glycerol, 200 mM imidazole), concentrated, and run over an analytical Superdex-75 column from 
Amersham Pharmacia on the ÄKTA FPLC system. Sample volume was 0.5 mL, run at 0.5 
mL/min in discobody storage buffer (200 mM NaCl, 20 mM Tris, pH 7.4). Typical yields were 1 
mg/L from yeast secretion culture.  
 
For E. coli expression, single colonies of BL21(DE3) containing the discobody construct in 
pET11a with a TEV-cleavable Strep-Tag II were picked and inoculated in 5 mL LB cultures with 
100 ug/mL amplicillin (LB-amp) and grown overnight at 37ºC, 250 RPM. The next day, we 
inoculated 4 L of LB-amp per clone, at 1 L per flask, with a 1:333 dilution of overnight culture 
and grew it at 37ºC until it reached an OD600 of 0.5. Cultures were inoculated with 1 mM IPTG 
and grown at 16ºC, 200 RPM, overnight to express protein. The following day, 4 L of the 
discobody clone were spun down and pooled, after which the pellet was split between two 50 mL 
conical Falcon tubes. The concentrated pellets were frozen at -20ºC then thawed at room 
temperature. Each 50 mL tube corresponded to 2 L worth of pellet and weighed 6.5 g. We added 
35 mL of BugBuster Master Mix from EMD Millipore to each 50 mL tube with heavy vortexing, 
then nutated the mix at room temperature for 30 minutes. This was then spun for 45 minutes at 
15,000 rcf, 4ºC on an angled rotor to separate the pellet from the discobody-containing 
supernatant. The resulting 30 mL of supernatant was poured into a new 50 mL tube and mixed 
with 6 mL of 5X StrepTactin binding/wash buffer (1X is 150 mM NaCl, 1 mM EDTA, 100 mM 
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Tris pH 8). This mix was run through equilibrated StrepTactin resin in a gravity column, 
washed once, then eluted in StrepTactin elution buffer (150 mM NaCl, 1 mM EDTA, 2.5 mM 
desthiobiotin, 100 mM Tris pH 8). Eluate was concentrated and purified by gel filtration using 
discobody storage buffer as described above. Yields were 1 mg/L.  
Binding kinetics in display 
Kinetics were performed as described [24]. All incubations were performed while nutating at 
room temperature. Quenched samples were placed on ice in a 4ºC cold room. All work with cold 
samples was performed at 4ºC with chilled tips and a dedicated cold room centrifuge. Samples 
were handled in 1.5 mL Eppendorf tubes, then transferred to a Nunc polypropylene 96-well V-
bottom plate prior to addition of secondary antibody for ease of handling and standardization 
between samples. Competition experiments were performed entirely in 96-well plates. Prior to 
flow cytometry analysis, samples were spun down and kept as pellets on ice, covered from light. 
Immediately prior to analysis, individual samples were resuspended in 0.5 mL of IBB and 
transferred to a polystyrene BD Falcon FACS tube for loading. 20,000 cell counts were collected 
for each sample in kinetic assays. Analysis was performed in GraphPad Prism version 6.0d for 
OSX 10.9 from GraphPad Software. Kd was fit to the Michaelis-Menten model, kon calculated 
association kinetics of two or more concentrations of hot ligand, and koff was determined via one 
phase exponential decay dissociation kinetics. kon values using one ligand concentration 
association kinetics were performed by constraining with the calculated koff and 200 nM hot 
ligand. Competition plots were fit to a five-parameter logistic equation for asymmetric sigmoidal 
curves, with the discobody competition plot being performed in duplicate. 
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Crystallization 
Initial crystal screening was performed using an Index screen (Hampton Research). Crystallization 
was conducted in 96-well plate format using a MRC sitting-drop crystallization plate (Hampton 
Research) at 20ºC; protein drops at 10 mg/mL were mixed with precipitant in a 0.5 µL x 0.5 µL 
ratio and were equilibrated with 50 µL of precipitant. Four initial hits were observed in 25% 
PEG3350 in different buffers. Upon crystal optimization, the best diffracting crystal was obtained in 
0.1 M Bis-Tris pH 6.5, 10% PEG750 methyl ether (Sigma). Crystals started to appear after four 
days and grew to maturation in a week with an approximate length of 300 µm. 
X-ray data collection and structure determination 
Crystals were harvested and soaked in a cryoprotectant solution containing Fomblin Y 16/6 
(Sigma). Crystals were frozen and sent to the Stanford Synchrotron Radiation Laboratory (SSRL). 
The diffraction data were collected at SSRL beamline 12-2 equipped with a PILATUS 6M PAD 
detector. The diffraction data were indexed, integrated, and scaled using XDS [120]. Initial phase 
was obtained by molecular replacement using PhaserMR [121] of the scaled experimental data 
using the previously solved C2 domain of human factor VIII [87] (PDB ID: 1D7P). Model building 
was done using Coot [122], and the structure was refined using Phenix.Refine [123]. Composite 
omit map was calculated using CCP4 suite [124]. 
Results  
The search process 
We set out to find a new scaffold by searching the RCSB protein data bank [125] for a protein 
that matched the following biophysical characteristics: monomeric, 1–50 kDa, and 25–100% β-
sheet. We hoped that a β-barrel scaffold would allow for a binding interface predicated on loops 
linking β-strands, much like the immunoglobulin β-sandwich fold [126]. In this case, we could 
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adopt many of the lessons learned from engineering loop-based binders and apply them to our 
scaffold, possibly also allowing loop grafting from known mAbs or other binding proteins. In 
addition to these biochemical search terms, we searched for “blood” or “serum” as keywords, and 
limited the search to human proteins. We expected that this constrained search would find a 
scaffold that behaved well as an intravenously injectable human therapeutic. An initial hit of the 
C2 discoidin domain of factor V, another blood coagulation factor, stood out to us. Upon further 
review of the discoidin domains involved in coagulation, we settled on the C2 domain of factor 
VIII, a very similar protein that has been more extensively characterized [83,84,86]. 
Display of template discoidin scaffold, loop grafting, and binding to integrin 
The C2 domain of fVIII contains hydrophobic residues on the most solvent-exposed tips of spikes 
1 and 3. Previous studies [83] have shown that mutating these residues (Met-Phe of spike 1 and 
Leu-Leu of spike 3) to Ala-Ala on each spike to produce a four-point mutant (called 4-Ala) 
results in a 35-fold reduction in binding to PS membranes and a 91% reduction in specific activity 
in the activated partial thromboplastin time assay, one way of measuring  fVIII activity. The 4-
Ala mutant C2 domain expresses in yeast surface display [22] format, so we used this approach to 
determine binding to our target protein, αvβ3 integrin, as measured by flow cytometry.  As shown 
in Fig. 2-2A, 4-Ala shows no inherent binding to αvβ3 integrin and was therefore chosen as our 
starting scaffold for engineering. 
 
To assess whether our discobody scaffold could bind a new target, we grafted a number of loops 
from αvβ3 binding proteins into the spike 1 region of the 4-Ala template, replacing the 
FTNAAAT spike 1 sequence. These sequences were taken from engineered integrin binding 
peptides (Fig. 2-2B–G) as well as fibronectin (Fig. 2-2H), which naturally binds αvβ3 
[43,70,71,116]. Of our seven loop grafts, four bound αvβ3 (Fig. 2-2C, E, G, and H). Based on 
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these data, we proceeded to build an RGD-containing degenerate codon library into spike 1 of 
4-Ala.  
Library generation and FACS selection 
We mutated the three most solvent-exposed amino acids at the tip of spike 1 to RGD, without 
changing its length, to ensure that the RGD motif was available to guide binding. Because both 
the position of RGD in the loop and its flanking amino acids significantly affect binding affinity 
[70,115,127], we randomly mutated two residues on each side of the motif using NNS degenerate 
codons. The FTNAAAT sequence of spike 1 was replaced with XXRGDXX, where “X” 
represents the NNS codon. NNS encodes all twenty amino acids as well as a single stop codon 
[128]. The theoretical library size was 1.6 x 105, and we were able to obtain ~1000-fold coverage, 
as we attained a transformation efficiency of 108 into the EBY100 yeast display strain.  
 
We expressed a library size of 109 and performed five sequential fluorescence-activated cell 
sorting (FACS) sorts with decreasing concentrations of αvβ3 integrin. Sorting against 200 nM for 
the first two sorts, 100 nM for the third and fourth sorts, and 10 nM for the final sort, we sorted 
the top 1-5% of each population for both antigen binding and surface display levels. We 
monitored each round by sequencing 10 clones each time. By round five, the XXRGDXX library 
converged upon a dominant clone with the loop sequence ACRGDTC (Fig. 2-3). This engineered 
variant (Eng-Db) was selected for further characterization and analysis. 
Binding and characterization of engineered discobody 
We measured binding kinetics of Eng-Db in yeast surface display format using soluble αvβ3 
integrin. Prior studies comparing yeast display measurements against other measurement formats 
show a strong correlation between display and conventional assays [33]. We examined kon by 
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incubating aliquots of the displayed discobody with 20, 50, and 100 nM αvβ3 integrin and 
quenching on ice at time points up to four hours. Quenching was performed by washing the 
sample in cold buffer and keeping it on ice until analysis. The kon was fit to 1.3 ± 0.2 (103 M-1s-1) 
(Fig. 2-4A, Supplementary Fig. 2-S2). This slow association may be due to the conformational 
change that αvβ3 integrin undergoes when binding to RGD-containing partners [129-131]. We 
measured koff by incubating yeast displaying Eng-Db with 200 nM antigen for four hours, 
washing aliquots at different time points, and leaving them with 1 uM soluble Eng-Db competitor 
at room temperature for intervals up to 26 hours to allow antigen dissociation. We calculated a koff 
of 2.0 ± 0.1 (10-5 s-1) and a t1/2 of 9.6 hours (Fig. 2-4B, Supplementary Fig. 2-S3). Using this koff 
value, we measured the kon again using a single concentration of 200 nM αvβ3 integrin and 
obtained a kon of 2.1 ± 0.4 (103 M-1s-1), which is similar to the value obtained using different 
antigen concentrations (Supplementary Fig. 2-S4). We also performed an equilibrium titration to 
determine Kd at equilibrium. Yeast displaying Eng-Db were incubated with varying 
concentrations of αvβ3 integrin (0–250 nM) for 24 hours. We measured a binding affinity of 16.2 
± 1.7 nM (Fig. 2-4C, Supplementary Fig. 2-S5). Binding measurements are summarized in Table 
I. 
 
To confirm that the discobodies function outside of display format, we expressed soluble 4-Ala 
and Eng-Db in both E. coli and S. cerevisiae hosts. Thermal stability was assessed using the 
Thermofluor denaturation assay [132], which yielded Tms of 55ºC and 61ºC for the 4-Ala and 
Eng-Db, respectively (Supplementary Fig. 2-S6). Both proteins show similar elution profiles via 
gel filtration and appear to be monomeric by comparison to FPLC standards (Supplementary Fig. 
2-S7). Using these purified proteins, we performed competition assays to see if either protein 
could prevent binding of displayed Eng-Db to αvβ3 integrin. Soluble Eng-Db prevented binding 
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in a dose-dependent manner, but soluble 4-Ala did not, indicating that Eng-Db functions 
outside of display (Fig. 2-5A, Supplementary Fig. 2-S8).  
 
Integrin αvβ3 naturally binds to the ECM protein fibronectin [116]. To see if our protein 
competes for the same binding site, we displayed fibronectin in yeast surface display and 
incubated it with αvβ3 integrin in the presence of soluble 4-Ala or Eng-Db. As before, Eng-Db 
blocked binding in a dose-dependent manner and 4-Ala did not, indicating that Eng-Db competes 
with the fibronectin binding site (Fig. 2-5B, Supplementary Fig. 2-S9).  
X-ray crystal structure of engineered discobody 
To gain further insight into Eng-Db, we obtained its crystal structure at 2.1 Å resolution (Fig. 2-
6A, Supplementary Table I).  The engineered variant looks very similar to previously solved 
wild-type fVIII C2 domain structures [87,127].  The C2 domain’s membrane-binding spikes 
exhibit some conformational heterogeneity, as illustrated in a structural overlay (Fig. 2-6C).  Eng-
Db’s loops fall within the observed range.  The RGD tripeptide motif is positioned at the most 
solvent exposed tip, as we had planned for during library design.  Note the presence of an 
additional disulfide bond within spike 1, which may account for the 6ºC increase in Tm (Fig. 2-
6A).  
Discussion 
Discoidin domain as an alternative scaffold 
The C2 discoidin domain of factor VIII has many attributes that make it a good alternative 
scaffold. Structurally, it is a β-barrel in the immunoglobulin superfamily that utilizes loops on one 
end for binding its cognate target (Fig. 2-1). The discoidin domain family binds many different 
targets in nature, and the β-barrel framework allows for diversity in the binding loops that in turn 
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allows for library construction [101]. Because the binding interface is made up of loops, 
similar to those of antibodies and engineered fibronectins [31,126], it is possible to transfer loops 
from preexisting binders onto the discobody scaffold, as has been demonstrated in our loop graft 
experiments (Fig. 2-2).  
 
Discobodies begin fully human, but loop mutations still need to be chosen with care to avoid 
introducing immunogenic sequences [106]. Certain hemophiliac patients who receive fVIII 
injections develop ADAs [89], but it seems unlikely that this would happen in an individual with 
endogenous fVIII due to negative selection during immune system development (personal 
communication, Gary Gilbert). 
αvβ3 integrin and RGD-containing peptides 
To minimize the number of variables while validating a new scaffold, we chose the well 
understood system of αvβ3 integrin and the RGD motif.  Additionally, αvβ3 integrin is over-
expressed in a number of cancers and is a drug target currently being pursued by the 
pharmaceutical industry [102].  
 
Our structure allows us to examine the presentation of the RGD tripeptide motif within Eng-Db.  
The distance between Cβ atoms of Arg and Asp has been found to influence binding to αvβ3 
integrin [115]. In that study, cyclic peptides with ArgCβ-AspCβ distances of 6.7 Å or less were 
optimal, with the lowest IC50 values (~50 nM) in an integrin-ECM competition assay.  Our 
measured Cβ-Cβ distance is 8.3 Å (Fig. 2-6B) but still provides a Kd in the low nanomolar range.  
While the assay systems and measurements are different, it is interesting to think about our results 
in the context of these studies.   
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αvβ3 bound to a cyclic Arg-Gly-Asp-{D-Phe}- {N-methyl-Val-} pentapeptide has been 
crystalized [130] (PDB ID: 1L5G).  The cyclic pentapeptide from this structure can be overlaid 
with spike 1 of Eng-Db (Supplementary Fig. 2-S10A), and the backbone RMSD of the respective 
Arg-Gly-Asp sequences is only 0.3 Å (Supplementary Fig. 2-S10B), demonstrating that the two 
binding sites may be very similar.  In Eng-Db, the Arg and Asp sidechains are directed away 
from each other, much like in the target-bound peptide.  Although the side chains differ slightly 
starting from their respective Cβs (Supplementary Fig. 2-S10A), their conformation may change 
upon binding to αvβ3 integrin.   
Future work for a universal discobody scaffold 
To truly be a universal alternative scaffold, discobodies will need to be engineered to bind a 
variety of targets. Future work will include building general libraries that are not RGD-focused. 
Our structure indicates that the C2 domain of fVIII can tolerate extensive mutations in its spikes 
and still retain its native fold (Fig. 2-6C). Additional work will be required to understand which 
residues can be engineered [38], if the spikes can tolerate length diversity [32,34], what range of 
antigens discobodies can bind [35,36], and what the affinity limits of this scaffold are [34]. 
Realizing the potential of bispecific discobodies and discobody-mAb fusions will require further 
study. Although the Tm of our template discobody (4-Ala) is 55ºC, it may be advantageous to 
engineer a more thermostable variant [133]; this would allow for greater diversity in library 
generation given that mutations often decrease thermal stability [34]. These efforts, however, will 
have to avoid introducing mutations that induce immunogenicity, which can arise from a single, 
erroneously placed point mutation [106]. 
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Conclusions 
Alternative scaffolds have found an important niche as complements to mAbs and are also being 
used to enhance binding as mAb fusions. Although many alternative scaffolds have entered the 
clinic, each has its strengths and weaknesses, requiring careful examination of the desired goals 
prior to scaffold selection. We saw the need for a new alternative scaffold that is tailored from the 
outset for use as a human therapeutic with bispecific capabilities. Discobodies are derived from a 
human protein and have a useful geometry with adjacent N- and C-termini, allowing for potential 
bispecific fusions with minimal linkers. Further work is needed to explore the potential of the 
discobody scaffold in protein engineering and drug development. 
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Figures and Tables 
  
Fig. 2-1. Topology diagrams comparing (A) the antibody immunoglobulin fold, (B) the discoidin 
domain, and (C) fibronectin. Structures of (D) the antibody VH domain of trastuzumab, (E) the 
C2 discoidin domain of factor VIII, and (F) the tenth repeat of fibronectin III. These correspond 
to PDB ID’s (D) 1N8Z, (E) 2R7E, and (F) 1FNA. N- and C-termini as well as binding loops are 
annotated. 
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 Fig. 2-2. Flow cytometry plots showing binding of 100 nM integrin to (A) 4-Ala and various 
loop grafts from known integrin-binding proteins, including (B-G) engineered knottins and (H) 
wild-type fibronectin. C, E, G, and H demonstrated binding to integrin. 
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Fig. 2-3. FACS plots for sequential sorts (A-E) of the library against decreasing concentrations of 
integrin. Red is the library with integrin, blue is without integrin and shows the level of 
background binding to secondary reagents. Sort gates and percentages of the library sorted are 
shown. 7/10 sequenced clones after sort five showed the (F) loop sequence ACRGDTC.  
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Fig. 2-4. Binding characterization of Eng-Db. (A) On rate measured with different concentrations 
of integrin. (B) Off rate measured with 200 nM integrin. (C) Equilibrium titration of displayed 
Eng-Db against integrin. 
 
 
 
Fig. 2-5. (A) Binding of displayed Eng-Db to 125 nM integrin with competing soluble 4-Ala or 
Eng-Db, performed in duplicate. (B) Binding of displayed fibronectin to 125 nM integrin with 
competing soluble 4-Ala or Eng-Db.  
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 Fig. 2-6.  (A) Cartoon representation of the Eng-Db structure with stick side chains in regions of 
interest; residues differing from wild type are shown in magenta, RGD is shown in red, the 
introduced disulfide bond in yellow, and mutations are labeled. (B) Line representation of spike 1 
with the Cβ-Cβ distance between Arg and Asp indicated with a dotted line.  (C) Ribbon overlay 
of the Eng-Db structure in red compared to wild-type structures of the C2 discoidin domain from 
fVIII: 1D7P in cyan, 3HNY in light green, and 3HOB in light pink; the Eng-Db ribbon is thicker 
for improved visualization. 
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 Supplementary Fig. 2-S1. Orientations of N- and C-termini of discobodies allow for shorter 
linkers. Bispecific domain schematics of (A) the mAb single-chain variable fragment and 
fibronectin compared to (B) the discobody.  Binding interfaces are shown in red.  
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Supplementary Fig. 2-S2. (A) Flow cytometry diagrams of displayed Eng-Db binding to 20, 
50, or 100 nM integrin over time. (B) Mean fluorescence intensity values of each population 
normalized between 0-1 for the lowest and highest signal. (C) Prism calculations for kon with two 
or more concentrations of hot ligand. 
  
48 
   
  
49 
Supplementary Fig. 2-S3. (A) Flow cytometry diagrams of displayed Eng-Db dissociating 
from 200 nM integrin in the presence of excess soluble Eng-Db competitor over time. (B) Mean 
fluorescence intensity values of each population normalized to 1 for the highest signal. (C) Prism 
calculations for koff with one phase exponential decay dissociation kinetics. 
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Supplementary Fig. 2-S4. (A) Flow cytometry diagrams of displayed Eng-Db binding to 200 
nM integrin over time. (B) Mean fluorescence intensity values of each population normalized 
between 0-1 for the lowest and highest signal. (C) Prism calculations for kon with single ligand 
concentration association kinetics, using koff values derived from Figure 4B. (D) Curve fit from 
calculations 
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Supplementary Fig. 2-S5. (A) Flow cytometry diagrams of displayed Eng-Db binding to 0-
250 nM integrin at equilibrium. (B) Mean fluorescence intensity values of each population 
normalized from 0-1 for 0-250 nM. (C) Prism calculations for Kd fit to the Michaelis-Menten 
model. 
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Supplementary Fig. 2-S6. Melting temperature (Tm) as assessed by the Thermofluor 
denaturation assay shows that Eng-Db is 6ºC more thermostable than 4-Ala. 
 
 
Supplementary Fig. 2-S7. Gel filtration profiles of soluble (A) 4-Ala and (B) Eng-Db. (C) 
Standards from the AKTA manual as comparison. 
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Supplementary Fig. 2-S8. (A) Flow cytometry diagrams of displayed Eng-Db binding to 125 
nM integrin in the presence of soluble competing 4-Ala or Eng-Db, performed in duplicate. (B) 
Mean fluorescence intensity values of each population normalized to 1 for the highest signal.  
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Supplementary Fig. 2-S9. (A) Flow cytometry diagrams of displayed fibronectin binding to 125 
nM integrin in the presence of soluble competing 4-Ala or Eng-Db. (B) Mean fluorescence 
intensity values of each population normalized to 1 for the highest signal.  
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 Supplementary Fig. 2-S10. (A) Line representations of spike 1 of Eng-Db (magenta) overlaid 
with that of the Arg-Gly-Asp-{D-Phe}- {N-methyl-Val-} integrin-binding cylic pentapeptide 
from the 1L5G αvβ3-RGD-Mn structure (cyan). RGD from spike 1 of Eng-Db is shown in red 
and the disulfide is in yellow; RGD from the pentapeptide is shown in blue. (B) Line 
representation of RGD backbones of spike 1 of Eng-Db (magenta) and pentapeptide (cyan); 
RMSD value for the RGD backbone only is 0.3 Å.  
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Table 2-I. Eng-Db binding and thermal stability characterization 
  
 
Kd (nM)          kon (10
3
 M
-1
s
-1
)         koff (10
-5
 s
-1
)         t1/2 (hours)         Tm (°C) 
16.2 ± 1.7         1.3 ± 0.2                    2.0 ± 0.1               9.6                     66 
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Supplementary Table 2-I. Data Collection and Refinement Statistics 
  
Data collection statistics 
PDB ID 4PT6  
Space group P1 
Unit cell 
a, b, c (Å) 32.45, 38.45, 48.84 
α, β, g (°) 98.56, 91.77, 111.03 
Wavelength (Å) 0.9795 
Resolution (Å) 31.15 - 2.10 
No. of unique reflections 11234 
Mean (I/σI) 15.4 (7.3) 
Completeness 88.6 (90.3) 
Average multiplicity 3.8 (3.8) 
Rmerge (%) 8.22 (14.9) 
Structure refinement statistics 
Resolution 31.15 - 2.10 
Average B factor (Å2) 45.9 
Rwork/Rfree (%) 19.88/25.20 
RMS deviations 
Bond length (Å) 0.006 
Bond angle (°) 1.2 
Ramachandran 
Favored (%) 97.7 
Outliers (%) 0 
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Rotamer outliers (%) 1.1 
MolProbity clashscore 9.27 
MolProbity overall score 1.61 
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A p p e n d i x  A  
DETAILED DISCOBODY DATA 
Here we present extensive data related to the Discobody engineering project that supports the main 
thesis body.  All methods were detailed in the preceding chapters, and will not be covered here.  
Due to the supplementary nature of the section, most information will be presented in figure format 
with corresponding legends. 
Figures and Tables 
 
Fig. A-1. Discoidin domain structural information. (A) The C2 domain of factor V (PDB ID: 
1CZT) was the first resulting hit from our PDB database search. (B) A structural overlay of 
discoidin domain family members from Kiedzierska, et al, illustrates the sequence diversity within 
the discoidin family, with diverse regions indicated as thick and conserved regions as thin.  Loops 
on top are attractive for including sequence diversity, such as libraries.  
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Fig. A-2. Factor VIII. (A) The complete fVIII structure (PDB ID 2R7E) with the C2 domain 
highlighted in dark grey. (B) The isolated C2 domain from the same structure. 
 
Fig. A-3. Hydrophobic residues mediate lipid binding. (A) The wild type fVIII C2 discoidin domain 
has Met-Phe and Leu-Leu, from left to right. (B) Our starting 4-Ala mutant has these four residues 
mutated to Ala-Ala and Ala-Ala. Mutations performed in Pymol. 
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Fig. A-4. αvβ3 integrin and the RGD motif. (A) αvβ3 integrin in black bound to an RGD peptide in 
red. (B) The discobody with the position of an inserted RGD noted in red. 
 
Fig. A-5. Yeast surface display schematic. (A) Diagram of yeast surface display constructs with 
biotinylated integrin, adapted from Chao, et al.  Antigen can either be biotinylated or stained with a 
specific antibody. (B) The layout of the discobody displayed on the yeast surface with bound 
integrin. 
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Fig. A-6. Flow cytometry plots demonstrate surface expression of 4-Ala discobody. (A) Display 
constructs with primary anti-cmyc antibody and secondary with fluorophore. (B) Secondary 
antibody only. 
 
Fig. A-7. Coomassie stain of soluble expression and purification from yeast of 4-Ala demonstrates 
that the starting template can be expressed outside of display format. 
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Fig. A-8. Flow cytometry plots of integrin binding AgRP control peptides from Silverman, et al, in 
display format. (A) With antigen, and (B) without antigen. Sequence of the binding loop is shown 
with RGD highlighted in red. 
 
 
  
66 
 
Fig. A-9. Affinity titration of control AgRP peptide against αvβ3 integrin, data are flow cytometry 
plots for displayed peptide. Incubation was performed for 1 hour at room temperature. 
 
Fig. A-10. Curve fit for AgRP and αvβ3 integrin based on data from Figure A-9.  
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Fig. A-11. Ribbon diagrams measuring backbone distances for loop grafting from onto (A) the 
discoidin domain. Loops containing RGD from (B) Fibronectin and (C) AgRP peptide were grafted 
onto the 4-Ala scaffold.  Measured distances indicated below in angstroms.  PDB IDs (A) 2R7E, 
(B) 1FNA, and (C) 1HYK. 
 
Fig. A-12. Close-up ribbon diagrams from Figure A-11.  
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Fig. A-13. Affinity titration of 4-Ala with the SGRGDNDLV loop graft against αvβ3 integrin via 
flow cytometry of displayed protein. 
 
Fig. A-14. Curve fit of Figure A-13 does not show a measureable affinity. 
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Fig. A-15. Affinity titration of 4-Ala with the AVTGRGDSPASS loop graft against αvβ3 integrin 
via flow cytometry of displayed protein. 
  
Fig. A-16. Curve fit of Figure A-15 demonstrates an affinity of 225.68 ± 30.47 nM at equilibrium. 
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Fig. A-17. Binding curves normalized by expression for AgRP (Figure A-10), JRC-5 
(SGRGDNDLV, Figure A-14), and JRC-11 (AVTGRGDSPASS, Figure A-16). 
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Fig. A-18. Library construction schematics. (A) Overlap PCR oligos for constructing the degenerate 
codon insert in green, RGD and flanking diverse regions shown in red. (B) Insert for cloning into 
blue pPNL6 yeast display vector via yeast homologous recombination.  
 
Fig. A-19. Percent lift of library population per FACS sorting round. Library “lift” is defined as the 
percentage of the displayed population that is lifted above baseline. Lift peaks after sort IV, 
indicating the selected population has plateaued. 
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Fig. A-20. Sequence diversity of each FACS sorting round of the library. Round I-III demonstrate 
no convergence. 
 
Fig. A-21. Sequences converge in sort round V. (A) VL, a minor population, converges upon 
RPRGDIE. (B) VR, the major population, converges upon ACRGDTC.  
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Fig. A-22. Overlaid flow cytometry plots for affinity titration of RPRGDIE in display format. αvβ3 
integrin was incubated with displayed RPRGDIE discobody for 30 minutes at room temperature 
and the geometric mean of the center of each population was used to calculate lift.  
 
Fig. A-23. Curve fit for RPRGDIE data from Figure A-22. 
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Fig. A-24. Overlaid flow cytometry plots for affinity titration of ACRGDTC in display format. 
αvβ3 integrin was incubated with displayed ACRGDTC discobody for 30 minutes at room 
temperature and the geometric mean of the center of each population was used to calculate lift. 
Later titrations were performed for much longer equilibrium times due to the slow on-rate. 
 
Fig. A-25. Curve fit for ACRGDTC data from Figure A-24. Later titrations with much longer 
equilibration times for the slow on-rate showed affinities an order of magnitude better. 
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Fig. A-26. Constructs for bacterial expression. Discobody constructs are separated by a TEV 
cleavable linker to the Strep-II tag. 
 
Fig. A-27. UV image of protein gel for soluble discobody clones. “S” is supernatant and “P” is 
pellet fraction. 4-Ala and ACRGDTC show expression in both fractions, RPRGDIE is primarily in 
the insoluble pellet. 
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Fig. A-28. TEV cleavage of ACRGDTC discobody (Eng-Db). (A) Cut and uncut schematics. (B) 
Protein gel of cut and uncut proteins show clear difference in molecular weight, “C” and “UC,” 
respectively. (C) Gel filtration of cut and uncut shows different elution times, the cut peak 
represents several milligrams of protein, while the uncut peak is 100 micrograms for comparison. 
 
Fig. A-29. Constructs for yeast secretion expression. Discobody constructs are separated by a TEV 
cleavable linker to a 6xHIS tag. Expression yields are shown. 
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Fig. A-30. Gel filtration and reducing SDS-PAGE gel of soluble discobodies from yeast. (A) Gel 
filtration data shows monomeric elution profiles for all three constructs, though RPRGDIE is 
slightly wider at its base. (B) SDS-PAGE gel of three constructs shows expected molecular weight. 
 
Fig. A-31. Yeast display levels of different discobody clones compared to scFv and fibronectin 
constructs.  
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Fig. A-32. Relative expression levels from Figure A-31 plotted. Expression levels correlate with 
known stabilities of each protein.  
 
Fig. A-33. Thermal melts of soluble discobody constructs via thermofluor denaturation. “RP” is 
RPRGDIE, “WT” is 4-Ala, and “AC” is ACRGDTC.  RPRGDIE precipitated shortly after 
expression. 4-Ala and ACRGDTC demonstrated stability for weeks in the cold room. Relative 
levels of display from Figure A-31 and A-32 correlate with soluble protein thermal stabilities.  
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Fig. A-34. Crystal collected for diffraction. 
  
Fig. A-35. Diffraction during pre-data collection. 
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Table A-1. Sequences of discobody constructs 
Wild type sequence of fVIII C2 domain : hydrophobic feet in bold, spikes 1-3 underlined in order. 
Sequence is residues L2171-Y2332 from 2R7E structure. 
 
LNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQ
DSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY 
4-Ala mutant : with MF/LL ! AA/AA mutations in bold, same underline scheme as above. 
LNSCSMPLGMESKAISDAQITASSYFTNAAATWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSAATSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQ
DSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY 
DNA sequence of 4-Ala mutant : XhoI cut site in bold, spike 1 underlined. This construct was used 
to clone degenerate codon libraries into pPNL6 yeast display vector. 
GCTAGCCTAAACAGCTGCTCTATGCCGTTGGGAATGGAATCAAAGGCGATCAGCGAC
GCTCAGATCACTGCCTCGAGCTATTTTACCAATGCTGCCGCCACATGGTCCCCTTCCA
AGGCGAGACTGCATTTGCAAGGTAGATCAAACGCGTGGAGACCACAAGTGAACAACC
CGAAAGAGTGGCTACAGGTGGACTTTCAGAAGACCATGAAGGTGACTGGCGTGACGA
CTCAGGGTGTAAAGTCAGCCGCGACCAGCATGTATGTCAAGGAGTTCTTGATCAGCTC
CAGCCAGGACGGGCACCAATGGACGCTTTTTTTCCAGAACGGTAAGGTTAAGGTGTTC
CAGGGAAACCAGGACTCATTTACGCCCGTGGTGAACAGCCTAGATCCCCCGTTGTTGA
CCAGATACTTGAGGATACACCCGCAGTCTTGGGTGCATCAAATTGCCTTGCGTATGGA
GGTATTGGGCTGTGAGGCTCAGGATCTGTATGGTTCCGGTAGC 
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RGD library schematic : NNS codons denoted with “X” and spikes 1-3 underlined in order. 
LNSCSMPLGMESKAISDAQITASSYXXRGDXXWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSAATSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQ
DSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY 
Eng-Db sequence : spikes 1-3 underlined in order. 
LNSCSMPLGMESKAISDAQITASSYACRGDTCWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSAATSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQ
DSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY 
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